Furthermore, a TRPM8 agonist increases cytosolic Ca2+, subsequently leading to activation of Ca2+-activated K+ channels that induce glioma cell migration (Wondergem and Bartley, 2009). Here, TRPM8 is linked to central nervous system cancer.